Bio-Rad projects 2025 currency-neutral revenue growth of 1.5%-3.5%, excluding contributions from acquisitions. Diagnostics revenue is expected to grow between 2%-3%, while Life Science revenue is ...

Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...

As an organization founded with an SBIR NIH/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial ...

The Chief Operating Offi­cer and Co-Founder of Syn­dicate Bio, Estelle Dogbo, has stated that the history of the company, Syndicate bio was founded in 2023 out of the realisation that glob­al research ...

Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides ...

This is a commentary manuscript, which aims to carry out a critical analysis of the effects of Pharmaceutical Care (PC) without the continuity of the service by healthcare professionals. PC has proven ...

DORADO, PUERTO RICO / ACCESS Newswire / January 29, 2025 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and ...

DORADO, PUERTO RICO / ACCESS Newswire / January 29, 2025 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and ...

The preclinical development of T-cell therapies will be managed by Moonlight Bio. Credit: murat photographer/Shutterstock. Leveragen has announced a strategic ...

About Pharma-Bio Serv, Inc. Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory ...